PT  - JOURNAL ARTICLE
AU  - Mohr, Nicholas M.
AU  - Plumb, Ian D.
AU  - Harland, Karisa K.
AU  - Pilishvili, Tamara
AU  - Fleming-Dutra, Katherine E.
AU  - Krishnadasan, Anusha
AU  - Hoth, Karin F.
AU  - Saydah, Sharon H.
AU  - Mankoff, Zachary
AU  - Haran, John P.
AU  - Briggs-Hagen, Melissa
AU  - León, Eliezer Santos
AU  - Talan, David A.
AU  - ,
TI  - Presence of Symptoms 6 Weeks After COVID-19 Among Vaccinated and Unvaccinated U.S. Healthcare Personnel
AID  - 10.1101/2022.02.16.22271092
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.16.22271092
4099  - http://medrxiv.org/content/early/2022/02/25/2022.02.16.22271092.short
4100  - http://medrxiv.org/content/early/2022/02/25/2022.02.16.22271092.full
AB  - Importance Although COVID-19 vaccines protect against infection and severe disease, the role of vaccination in preventing prolonged symptoms in those with subsequent infection is unclear.Objective To determine differences in symptoms stratified by prior vaccination reported by healthcare personnel (HCP) 6 weeks after onset of COVID-19, and whether there were differences in timing of return to work.Design Nested cohort study within a multicenter vaccine effectiveness study. HCP with COVID-19 between December 2020 and August 2021 were followed up 6 weeks after illness onset.Setting Health systems in 12 U.S. states.Participants HCP participating in a vaccine effectiveness study were eligible for inclusion if they had confirmed COVID-19 with either verified mRNA vaccination (symptom onset ≥14 days after two doses) or no prior COVID-19 vaccination. Among 681 eligible participants, 419 (61%) completed a follow-up survey approximately 6 weeks after illness onset.Exposures Two doses of a COVID-19 mRNA vaccine compared with no COVID-19 vaccine.Main outcomes and measures Presence of symptoms 6 weeks after onset of COVID-19 illness and days to return to work after COVID-19 illness.Results Among 419 HCP with confirmed COVID-19, 298 (71%) reported one or more COVID-like symptoms 6 weeks after illness onset, with a lower prevalence among vaccinated participants (60.6%) compared with unvaccinated participants (60.6% vs. 79.1%; aRR 0.70, 95% CI 0.58-0.84). Vaccinated HCP returned to work a median 2.0 days (95% CI 1.0–3.0) sooner than unvaccinated HCP (aHR 1.37; 95% CI, 1.04–1.79).Conclusions A history of two doses of COVID-19 mRNA vaccine among HCP with COVID-19 illness was associated with decreased risk of COVID-like symptoms at 6 weeks and earlier to return to work. Vaccination is associated with improved recovery from COVID-19, in addition to preventing symptomatic infection.Question Does vaccination lead to improved recovery of symptoms and return to work following COVID-19?Findings In this nested cohort study of healthcare personnel, participants with COVID-19 who had received two doses of a COVID-19 mRNA vaccine were less likely to report symptoms 6 weeks after illness onset than participants with COVID-19 who were unvaccinated. Return to work was sooner if previously vaccinated.Meaning Vaccination is associated with improved recovery from COVID-19, in addition to prevention of infection and disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Centers for Disease Control and Prevention (CDC) (U01CK000480). The project is additionally supported by the Institute for Clinical and Translational Science at the University of Iowa through a grant from the National Center for Advancing Translational Sciences at the National Institutes of Health (UL1TR002537).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy. All participants provided informed consent prior to participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.